Targeted therapy slows disease progression for prostate cancer

Targeted therapy slows disease progression for prostate cancer

Targeted therapy slows disease progression and improves survival for prostate cancer

• Download PDF Copy

By Sally Robertson, B.Sc.Oct 2 2019Reviewed by Kate Anderton, B.Sc. (Editor)

Clinical trial data presented on Monday at the European Society for Medical Oncology (ESMO) Congress showed that a PARP-inhibitor significantly delayed cancer progression among patients with pre-treated prostate cancer who had cancer cells with faulty DNA repair genes.